{
  "compound": "Pharmaceutical-grade CBD (Epidiolex)",
  "condition": "EPILEPSY",
  "effect_size": "N/A (guideline)",
  "study_type": "CLINICAL_GUIDELINE",
  "source": "NORML:EPILEPSY_GUIDELINE_001",
  "participants": "Evidence-based guideline",
  "year": 2018,
  "notes": "AAN/AES Practice Guideline: Cannabidiol for Treatment-Resistant Epilepsy",
  "confidence": "medium",
  "abstract": "Level B recommendation for adjunctive CBD in Dravet and LGS; Evidence sufficient for clinical use; Monitoring recommendations provided"
}